On Oct 31, major Wall Street analysts update their ratings for $Tenet Healthcare (THC.US)$, with price targets ranging from $183 to $217.
Goldman Sachs analyst Jamie Perse maintains with a buy rating, and adjusts the target price from $173 to $196.
BofA Securities analyst Joanna Gajuk maintains with a buy rating, and maintains the target price at $189.
UBS analyst A.J. Rice maintains with a buy rating, and adjusts the target price from $164 to $217.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and adjusts the target price from $136 to $183.
Truist Financial analyst David S Macdonald maintains with a buy rating, and adjusts the target price from $180 to $190.
Furthermore, according to the comprehensive report, the opinions of $Tenet Healthcare (THC.US)$'s main analysts recently are as follows:
Tenet Healthcare displayed a robust performance across its various segments for the third quarter, particularly noting strong results from the hospital segment, with the USPI segment meeting expectations. The company is focusing on channeling investments towards the USPI segment as its primary capital allocation, while also continuing to seek growth opportunities within its hospitals, especially after refining its portfolio through a series of divestitures.
Tenet Healthcare demonstrated a notable recovery from previous weaknesses in the hospital segment, underscored by a robust third-quarter performance and an upward revision of future guidance. The company's preliminary outlook for 2025 indicates a persistence of robust volume trends into the upcoming year, alongside ongoing expansion of capacity.
Here are the latest investment ratings and price targets for $Tenet Healthcare (THC.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$泰尼特 (THC.US)$的評級，目標價介於183美元至217美元。
高盛集團分析師Jamie Perse維持買入評級，並將目標價從173美元上調至196美元。
美銀證券分析師Joanna Gajuk維持買入評級，維持目標價189美元。
瑞士銀行分析師A.J. Rice維持買入評級，並將目標價從164美元上調至217美元。
加皇資本市場分析師Ben Hendrix維持買入評級，並將目標價從136美元上調至183美元。
儲億銀行分析師David S Macdonald維持買入評級，並將目標價從180美元上調至190美元。
此外，綜合報道，$泰尼特 (THC.US)$近期主要分析師觀點如下：
以下爲今日5位分析師對$泰尼特 (THC.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
